Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ranolazine on exercise-induced myocardial perfusion defects assessed by SPECT
2011-001516-54Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ranolazine in coronary arteriosclerosis and cardiac ischemia (2 arms), sponsored by Gilead Sciences. Started Jul 2011; status: completed.
02
Drugs
ranolazine
03
Conditions
coronary arteriosclerosiscardiac ischemia
Beyond the preview
Go deeper on 2011-001516-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001516-54.